Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Radiotherapy in HPV-Positive Oropharyngeal Cancer
NCT03410615Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2018
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
A Phase 2 trial of durvalumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Canadian Cancer Trials Group. Started May 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03410615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410615.